Redsense Medical Reports Increased Sales and Improved Result in Q2 2026
Redsense Medical AB (publ.) announced a second-quarter report for 2026 showing increased net sales and a positive operating result. The company also launched a new digital product.
Redsense Medical AB (publ.) has released its interim report for the second quarter of 2026, covering April to June. The company reported net sales of kSEK 7,090, an increase from kSEK 6,276 in the same period last year.
The operating result (EBIT) for the quarter turned positive, reaching kSEK 377 compared to a loss of kSEK -1,833 in the prior year. Excluding exchange rate differences, the operating result was kSEK 452, up from kSEK -750. The result after tax was kSEK 421, a significant improvement from kSEK -1,830 in the second quarter of 2025.
Earnings per share were SEK 0.03, compared to SEK -0.11 in the corresponding period of the previous year. Exchange rate differences impacted the result by kSEK 75, a decrease in negative impact compared to kSEK -1,083 in the prior year.
During the period, the Annual General Meeting on May 20 elected Michael Kraus as a new director until the end of the next AGM. On June 26, Redsense announced the launch of a new digital product, with further details expected to be disclosed.